Recursion Pharmaceuticals (RXRX) Treasury Shares (2020 - 2026)

Recursion Pharmaceuticals' Treasury Shares history runs 7 years deep, the most recent figure standing at $28.6 million for Q1 2026.

• Quarterly Treasury Shares rose 9.14% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (up 9.14% YoY) and the FY2025 annual result came in at $27.5 million, up 0.68% from the prior year.
• Treasury Shares was $28.6 million for Q1 2026 at Recursion Pharmaceuticals, up from $27.5 million in the prior quarter.
• Across five years, Treasury Shares topped out at $30.6 million in Q3 2025 and bottomed at $6.9 million in Q4 2022.
• A 5-year average of $19.2 million and a median of $18.5 million in 2023 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2023 — Treasury Shares surged 153.92% — and 2025, when it gained 0.68%.
• Recursion Pharmaceuticals' Treasury Shares stood at $6.9 million in 2022, then surged by 120.81% to $15.2 million in 2023, then jumped by 79.35% to $27.3 million in 2024, then rose by 0.68% to $27.5 million in 2025, then increased by 3.91% to $28.6 million in 2026.
• Business Quant data shows RXRX's Treasury Shares at $28.6 million in Q1 2026, $27.5 million in Q4 2025, and $30.6 million in Q3 2025.